Despite therapy advances, acute kidney damage (AKI) remained a severe problem for cancer patients. For a study, the researchers sought to determine the prevalence of AKI in cancer patients and the risk factors associated with it. During 2016–2018, retrospective cohort research was done at tertiary hospitals. To collect associated information from patients’ records, a data abstraction sheet was used. Creatinine levels were used to estimate the occurrence of AKI during admission. It was classified into 5 severity levels using RIFLE criteria: risk, injury, failure, loss, and end-stage renal disease. Furthermore, 6.9% of hospitalizations were complicated by AKI, according to RIFLE (Risk, Injury, Failure, Loss, and End-stage renal disease) criteria. The seriousness of these was 3.3%, 1.7%, and 1.9%, respectively, in the risk, harm, and failure categories. The odds of developing AKI were significantly higher in the multivariate model for patients with congestive heart failure (AOR=17.1, 95% CI 1.7–80.1), chronic kidney disease (adjusted OR=6.8, 95% CI 1.4–32.2 (P-value 0.017)), sepsis (AOR=4.4, 95% CI 1.9–10.1), hypercalcemia (AOR=8.4, 95% CI 1.3–46.1), and admission to the ICU (AOR=5.8, 95% CI 2.1–16.2). Furthermore, individuals with AKI had a nearly 7-fold greater mortality rate (relative risk=7.6, 95% CI 3.2–18.2). In cancer patients, AKI was linked to worse outcomes and greater mortality rates and congestive heart failure, chronic renal disease, sepsis, ICU hospitalization, and hypercalcemia. AKI testing for hospitalized cancer patients was done frequently, especially for those at higher risk.